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Abstract
Background: Recurrent and especially chronic headaches are associated with psychiatric comorbidities such as
depression and anxiety. Only few studies examined the impact of depression and anxiety on episodic (EH) and
chronic headache (CH), and data for Austria are missing at all. Therefore, the aim of the present study was to assess
the impact of depression and anxiety on burden and management of EH and CH in patients from eight Austrian
headache centres.
Methods: We included 392 patients (84.1 % female, mean age 40.4 ± 14.0 years) who completed the Eurolight
questionnaire. The treating physician recorded details about ever-before prophylactic medications. We used
Hospital Anxiety and Depression Scale to assess depression and anxiety and compared patients with anxiety and/or
depression to those without.
Results: Depression and anxiety were more common in CH than in EH (64 % vs. 41 %, p < 0.0001). Presence
compared to absence of depression and anxiety increased the prevalence of poor or very poor quality of life from
0.7 % to 13.1 % in EH and from 3.6 % to 40.3 % in CH (p = 0.001; p < 0.0001). Depression and anxiety had a
statistically significant impact on employment status and on variables related to the burden of headache such as
reduced earnings, being less successful in career, or feeling less understood. Neither in EH nor in CH health care
use and the ever-before use of prophylactic medication was correlated with anxiety and/or depression.
Conclusion: Depression and anxiety have a significant impact on quality of life and increase the burden in patients
with EH and CH. Improved multidimensional treatment approaches are necessary to decrease disability on the
personal, social and occupational level in these patients.
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Background
Headache is a frequent disorder with one-year preva-
lence rates of 10 – 18.6 % for migraine and 31 – 90 %
for tension-type headache, and it is often interfering with
everyday life [1–3]. Headache, especially migraine, is as-
sociated with comorbidities such as anxiety disorders
and depression, ranging from 18 – 58 % for anxiety dis-
orders and 17 – 47 % for depression [4–7]. In addition,
headache patients, especially those with migraine or
chronic daily headache, showed reduced quality of life
[8, 9], and the burden caused by any headache is high
with regard to lost workdays, lost days with household
activities, lost family, social and leisure activities [10, 11].
Recent studies showed that significantly more patients
with chronic migraine suffer from psychiatric comorbidi-
ties than patients with episodic migraine (31 – 58 % vs.
17 – 30 %), and that patients with chronic migraine had
lower household incomes and were less likely to be
employed fulltime [4, 5, 9].
To assess the prevalence of episodic headache (EH)
and chronic headache (CH), management and burden of
EH and CH in patients in Austrian headache centres, we
performed a prospective, multicentre study in eight
headache centres published in 2015 [11]. Within this
study we collected also data on depression and anxiety.
Depression and anxiety may cause additional burden in
headache sufferers with respect to productivity loss,
quality of life, health care utilization, and emotional bur-
den. So far only few studies addressed the impact of psy-
chiatric comorbidities in patients with migraine and
headache in general [12–14]. None of these studies com-
pared EH to CH and data for Austria are missing at all.
Therefore the aim of the present study was to assess
the impact of depression and anxiety on burden and
management of patients with EH and CH from eight
Austrian headache centres.
Methods
In April 2011 and September 2011 all consecutive pa-
tients attending one of eight Austrian headache centres
for a first-time or follow-up visit were invited to partici-
pate in the study. Inclusion criteria were age ≥18 years,
primary headache, medication overuse headache, and
fluent German. Exclusion criteria were secondary head-
aches except medication overuse headache, fibromyalgia,
other chronic pain disorders, and lacking knowledge of
German. Four centres were at departments of medical
universities, three centres were at large hospitals, and
one centre was a large neurological office in Vienna. The
study was approved by the ethics committee of the Med-
ical Universities of Vienna, Graz, Innsbruck and Salz-
burg and local ethics committees of the other
participating departments.
After giving written informed consent the patients
completed the Eurolight questionnaire once. The Euro-
light questionnaire was developed to gather data on the
personal, social and economic impact of migraine, TTH
and MOH in 15 countries in the European Union (EU)
[10, 15]. It is a 103-item self-reporting questionnaire,
validated in five languages, with good construct validity,
good test-retest reliability and good internal consistency
[15]. The questionnaire covers biographic data, headache
symptoms, use of acute and prophylactic medications
during the previous month, former examinations due to
headache, quality of life as well as symptoms of anxiety
and depression. The Eurolight questionnaire differenti-
ates EH, i.e. headache on <15 days/month, and CH, i.e.
headache on ≥15 days/month, and it is validated for
diagnosing migraine, probable migraine, tension -type
headache (TTH), probable tension-type headache
(pTTH) and probable medication overuse headache
(pMOH) according to ICHD-2 [15, 16]. Other headaches
than mentioned above are classified as “other headache”.
It does not allow diagnosing the underlying headache in
patients with CH and pMOH. Therefore we diagnosed
these patients based on their questionnaire entries con-
cerning their most bothersome headache.
The questionnaire also includes the HALT index
(Headache-attributed lost time index) for assessing days
lost completely or partially because of headache [10, 17],
the WHOQoL-8 (WHO quality of life assessment) [18],
and the Hospital Anxiety and Depression scale (HADS)
[19]. The HALT index captures in five questions the
days lost completely or partially because of headache in
the preceding three months and covers professional
work, household activities or chores, and family, social
or leisure activities. To estimate the burden of headache,
and because data were not normally distributed, we
summarized these lost days during the previous three
months and categorized the impact of headache into 0-5
days lost, 6-10 days lost, 11-20 days lost, and >20 days
lost. We assessed the patients’ quality of life by using the
first question of the WHOQoL-8 that asks the patients
to rate their general quality of life on a five-point scale
(poor, very poor, neither good nor poor, good, very good)
[18], and we used the HADS for assessing anxiety and
depression [19]. The HADS has seven items each for
assessing anxiety and depression. Anxiety or depression
was rated as present if the HADS-A score or the HADS-
D score was ≥8 [19]. If one of the subscales indicated de-
pression or anxiety and the other subscale was missing,
we rated depression and/or anxiety as present. If one
subscale was not indicative of anxiety or depression and
the other subscale was missing, we rated depression and
anxiety data as missing.
In addition to the questionnaire completed by the pa-
tients, the treating neurologist filled in a questionnaire
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covering the clinical headache diagnosis and ever-before
intake of five classes of standard prophylactic medication
(betablocker, flunarizine, valproate, topiramate, amitrip-
tyline). For each of these drug classes the treating neur-
ologist had to assess, if it was contraindicated and if it
was ever taken by the patient. If it had ever been taken,
four additional questions had to be answered: (1) Was
the treatment stopped because of intolerable adverse ef-
fects, (2) was the dose sufficient according to national
and international guidelines [20, 21], (3) was the drug
taken for at least three months, and (4) was headache
frequency decreased by at least 50 % while taking this
prophylactic drug?
For the initial study we screened 598 consecutive pa-
tients, 121 patients denied participation or had to be ex-
cluded, mainly because of lacking fluency in German, 36
questionnaires had to be excluded for incomplete data.
Thus the analysis was based on 441 patients [11], of
these 56.3 % had EH, 38.3 % had CH, and patients with
CH had a significantly lower quality of life and signifi-
cantly more often depression or anxiety [11]. For the
present study we included all patients with available data
on headache frequency in the Eurolight questionnaire
and on prophylactic medication in the questionnaire
completed by the treating neurologist.
Statistics
We applied the standard computerized algorithm to
analyse data derived from the Eurolight questionnaire
[22]. We compared patients with EH to patients with
CH, and for assessing the impact of depression and
anxiety we compared patients with depression and/or
anxiety and without depression and/or anxiety both
in patients with EH and CH. We used numbers and
percentages for descriptive statistics and Chi2-tests for
comparing patients with and without depression and/
or anxiety differentiating EH and CH. For compari-
sons of continuous variables we used t-tests. We cal-
culated odds ratios to assess the risk of burden for
presence versus absence of depression and/or anxiety
in the entire group of patients and in those with EH
and CH. For assessing the impact of depression and
anxiety on the use of five classes of standard prophy-
lactic medications we dichotomized ever-before use,
contraindications, adverse effects, use for at least
three months, intake of an adequate dose, and de-
crease in headache frequency by at least 50 % and
compared presence in none versus presence in one or
more of the drugs. Two-sided p-values < 0.05 were
considered as statistically significant. As this was an
exploratory study, we did not correct for multiple
testing. Standardized Eurolight analyses were done
with SAS 9.2, all other statistical analyses were per-
formed using SPSS 20.0.
Results
We included 392 patients with available data on head-
ache frequency in the Eurolight questionnaire and with
the completed additional questionnaire filled-in by the
treating neurologist. Table 1 shows gender, depression
and/or anxiety and headache diagnoses in EH compared
to CH. Of 392 patients 301 (79.1 %) were female, 82
(20.9 %) male. The proportion of males was significantly
higher among patients with CH (Table 1). Two-
hundred-thirty-two patients (59.2 %) had EH, and 160
(40.8 %) patients had CH, among the latter 65 (40.6 %)
had pMOH. Patients with EH and CH did not differ in
age (40.3 ± 13.3 vs. 40.4 ± 14.9 years, p = 0.9). In EH 92
patients (40.2 %) and in CH 97 patients (63.8 %) had de-
pression and anxiety or at least one of these psychiatric
disorders (p < 0.0001). The prevalence of depression
alone and anxiety alone was significantly higher in pa-
tients with CH (depression 43.6 %, anxiety 53.9 %) than
in patients with EH (depression 22.8 %, anxiety 34.1 % p
< 0.0001 (Table 1). Regarding headache diagnoses 199
(85.8 %) patients with EH had migraine; among the pa-
tients with CH 69 (43.1 %) had migraine, and 65
(40.6 %) had pMOH (Table 1).
Table 1 Gender, depression, anxiety and headache diagnoses in
patients with EH and CH
EH (n = 232) CH (n = 160)
Patients Patients Chi2 p
n % n %
Sex
Female 198 84.1 112 71.9 13.5 <0.0001
Male 34 15.9 48 28.1
Anxiety
Missing data: 9
Yes 78 34.1 83 53.9 14.9 <0.0001
No 151 65.9 71 46.1
Depression
Missing data: 19
Yes 51 22.8 65 43.6 18.2 <0.0001
No 173 77.2 84 56.4
Anxiety and/or depression
Missing data: 14
Yes 92 40.7 97 63.8 19.4 <0.0001
No 134 59.3 55 36.2
Headache diagnosis
Migraine 199 85.8 69 43.1 79.7 <0.0001
Tension-type HA 27 11.6 22 13.8 ns
Other HA 6 2.6 4 2.5 ns
pMOH - - 65 40.6 na
EH episodic headache, CH chronic headache, pMOH probable medication
overuse headache, ns not significant; na not applicable
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Looking at EH and CH patients separately, the mean
age did not differ between with and without depression
and/or anxiety: EH with depression and/or anxiety 39.7
± 12.3 years, EH without depression and/or anxiety 41.2
± 14.6 years; CH with depression and/or anxiety 38.8 ±
14.3 years, CH without depression and/or anxiety 41.6 ±
15.6 years. Also gender did not differ significantly be-
tween patients with and without depression and/or anx-
iety (Table 2). Table 2 shows the impact of anxiety and
depression on patients with EH and CH. Headache diag-
noses did not depend on presence or absence of anxiety
and/or depression. Both in EH and CH significantly
more patients with depression and/or anxiety had a worse
quality of life (poor or very poor quality of life in EH 12 pa-
tients (13.1 %), in CH 30 patients (31.3 %), p < 0.0001),
higher unemployment rates (in EH 23 patients (26.4 %), in
CH 42 patients (45.2 %), p < 0.0001), and missed the feeling
of being understood by colleagues/employers (in EH 27 pa-
tients (48.2 %), in CH 27 patients (51.9 %), p = 0.039). In
EH but not in CH significantly more patients with depres-
sion and/or anxiety reported that they had been less suc-
cessful in their careers, had reduced earnings due to
headaches, and that they felt less understood by their fam-
ilies (Table 2). In CH but not in EH significantly more pa-
tients with depression and/or anxiety avoided telling other
people about their headaches, and the number of patients
who lost more than ten days because of headache during
the previous three months was higher in those with depres-
sion and/or anxiety; but the latter did not reach statistical
significance. In both groups the interference with education
and the feeling of being in control of the headache was in-
dependent of depression and/or anxiety (Table 2).
These findings appeared even more pronounced using
risk calculations (Table 3). Analysing all patients the
presence of depression and/or anxiety increased the risk
of CH (OR 2.5) and pMOH (OR 2.48), it markedly de-
creased quality of life and it increased burden. The risk
of poor or very poor quality of life was almost 18-fold
higher in patients with depression and/or anxiety com-
pared to those without. The burden was higher for seven
of the other nine variables with odds ratios ranging from
1.75 to 4.8 (Table 3). Assessing the impact of depression
and/or anxiety separately for EH and CH the odds ra-
tio for poor or very poor quality of life was 19.95 and
12.05, respectively, and the burden was increased in
EH and CH in six and four of the other nine vari-
ables showing odds ratios of 2.2. to 4.5 and 2.15 to
6.3, respectively (Table 3).
Patients with CH consulted general practitioners sig-
nificantly more often than patients with EH (61/39.1 %
vs. 65/29.1 %; p = 0.043), consultations of other health
care professionals did not differ between patients with
EH and CH. Depression and/or anxiety had no impact
on headache-related health care consultations (headache
specialist, general practitioner, hospital emergency room,
nurse, physical therapist) and examinations (magnetic
resonance imaging, computer tomography, X-ray, eye
test, blood tests) during the previous 12 months in EH
and CH. The impact of depression and/or anxiety on the
use of five classes of standard prophylactic medications
was minimal. In EH but not in CH patients with depres-
sion and/or anxiety had significantly more contraindica-
tions than those without (EH without depression and/or
anxiety 29 patients (23.2 %), EH with depression and/or
anxiety 31 (36.5 %), p = 0.037; CH without depression
and/or anxiety 12 patients (22.6 %), CH with depression
and/or anxiety 18 (20.9 %), p > 0.05. Neither in EH nor
in CH ever-before use of prophylactics, adverse effects,
use for at least three months, intake of an adequate dose
and decrease of headache frequency by at least 50 % was
statistically associated with depression and/or anxiety
(Table 4).
Discussion
This post-hoc analysis of a prospective, cross-sectional
multicentre study in eight Austrian headache centres
showed a significantly higher prevalence of anxiety and/
or depression in CH (64 %) than EH (41 %). Depression
and anxiety had a marked impact on quality of life and
increased the burden in patients with EH and CH as
well as in the entire group of patients. Patients with de-
pression and/or anxiety had statistically a higher risk of
CH and pMOH. In contrast, diagnostic and therapeutic
management of headache was unrelated to the presence
of depression and/or anxiety with only one single excep-
tion, i.e. an increased risk of contraindications against
standard prophylactic medications in EH.
These findings replicated in a clinic-based population
well-known findings that patients with CH suffer from
depression and/or anxiety more often than patients with
EH [1, 9, 23–26], including suicidal attempts as shown
in the literature [27]. Based on the concept of stagnation,
Innamorati et al. [28, 29] showed that patients with
medication overuse headache are burdened with a com-
bination of psychological, behavioural and physical
symptoms, and that in chronic migraine stagnation,
characterized by feelings of obstruction of body, emo-
tions and behaviour, is associated with depression. The
impact of depression and anxiety on burden is much less
known, however, and has been examined in three studies
only [12–14]. A study in patients with chronic migraine
and medication overuse found that depressive symptoms
in these patients were associated with higher disability
and lower quality of life [12]. Patients with posttraumatic
stress disorder and migraine were more likely to be in
the low poverty index and less likely to work for pay
than patients with migraine alone, their work quality
was cut 2.5-fold greater than in patients with
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Table 2 Gender, headache diagnoses and burden of headache in patients with EH and CH with and without depression and/or
anxiety. HADS scores ≥8 indicate presence of depression and/or anxiety, HADS scores <8 indicate absence of depression and/or
anxiety
EH (n = 232) Statistics CH (n = 160) Statistics
Anxiety and/or depression Anxiety and/or depression
Absent Present Absent Present
Patients Patients Chi2 p Patients Patients Chi2 p
n % n % n % n %
Sex
Missing data: 14 ns ns
Female 112 83.6 80 87 35 63.6 70 72.2
Male 22 16.4 12 13 20 36.4 27 27.8
Headache diagnosis
Missing data: 14
Migraine 113 84.3 82 89.1 *ns 24 43.6 43 44.3 *ns
Tension-type headache 18 13.3 7 7.6 *ns 12 21.8 10 10.3 *ns
pMOH - - - - - 19 34.5 41 42.3 *ns
Other headache 3 2.2 3 3.3 *ns 0 0 3 3.1 *ns
Quality of life
Missing data: 15 40.8 0.001 32.6 <0.0001
Very good 34 25.4 11 12 17 30.9 5 5.2
Good 87 64.9 39 42.4 23 41.8 26 27.1
Neither good nor poor 12 9 30 32.6 13 23.6 35 36.5
Poor 1 0.7 9 9.8 1 1.8 19 19.8
Very poor 0 0 3 3.3 1 1.8 11 11.5
Employment status
Missing data: 31 10.0 0.002 17.0 <0.0001
Employed 116 89.9 64 73.6 46 88.5 51 54.8
Unemployed/retired 13 10.1 23 26.4 6 11.5 42 45.2
Lost days in preceding 3 months**
Missing data: 56 ns ns
0-5 41 32.3. 23 28.4 13 26.5 10 12.7
6-10 21 16.5 14 17.3 3 6.1 3 3.8
11-20 27 21.3 13 16 7 14.3 11 13.9
>20 38 29.9 31 38.3 26 53.1 55 69.6
Headache interfered with education
Missing data: 20 ns ns
Yes 38 29 36 39.6 20 37 45 46.9
No 93 71 55 60.4 34 63 51 53.1
Less successful in career due to HA
Missing data: 22 7.3 0.007 ns
Yes 34 25.8 38 43.2 20 37 49 51
No 98 74.2 50 56.8 34 63 47 49
Reduced earnings due to HA
Missing data: 57 9.1 0.003 ns
Yes 11 9.1 20 24.7 9 20 31 35.2
No 110 90.9 61 75.3 36 80 57 64.8
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migraine alone, and their difficulties getting along
with social life were 2-fold greater than in patients
with migraine alone [13].
Recurrent or chronic headache and psychiatric comor-
bidities interact in a complex manner. Some longitudinal
studies found clues for a bidirectional association: In
adolescents anxiety and depression were associated with
recurrent migraine (not tension-type headache) after
four years [30], a higher migraine frequency was associ-
ated with higher depression and anxiety scores [31], de-
pression and anxiety were significant risk factors for the
chronification of migraine [12, 32, 33]. The risk of
Table 2 Gender, headache diagnoses and burden of headache in patients with EH and CH with and without depression and/or
anxiety. HADS scores ≥8 indicate presence of depression and/or anxiety, HADS scores <8 indicate absence of depression and/or
anxiety (Continued)
HA understood by colleagues/employer
Missing data: 157 11.5 0.001 4.3 0.039
Yes 73 78.5 29 51.8 24 70.6 25 48.1
No 20 21.5 27 48.2 10 29.4 27 51.9
HA understood by family
Missing data: 25 8.8 0.003 ns
Yes 128 96.2 74 85.1 49 90.7 76 81.7
No 5 3.8 13 14.9 5 9.3 17 18.3
Avoid telling people about HA
Missing data: 19 7.8 0.05 4.9 0.028
Yes 33 24.8 38 42.7 19 34.5 51 53.1
No 100 75.2 51 57.3 36 65.5 45 46.9
Feeling of being in control of the headaches
Missing data: 18 ns ns
Yes 91 67.9 58 65.2 34 63 52 53.6
No 43 32.1 31 34.8 20 37 45 46.4
*compared to all remaining diagnoses, ** including lost workdays, lost housework days, workdays and housework days with productivity reduced to < 50 %, and
lost days with leisure or family activities. ns not significant, na not applicable
Table 3 Odds ratios of having greater burden for presence versus absence of depression and/or anxiety
All patients (n = 392) EH (n = 232) CH (n = 160)
OR CI OR CI OR CI
Being male 1.1 0.67-1.80 0.76 0.36-1.63 0.68 0.33-1.37
Having chronic headache 2.57 1.68-3.93 na na na na
Having migraine 1.35 0.87-2.10 0.66 0.29-1.47 1.03 0.53-2.00
Having pMOH 2.48 1.88-4.46 na na 1.39 0.70-2.76
Having poor/very poor quality of life 17.84 5.42-58.70 19.95 2.55-156.33 12.05 2.75-52-72
Being unemployed/retired 4.8 2.7-8.5 3.21 1.52-6.76 6.31 2.46-16.22
Having ≥11 lost days in preceding 3 months 1.75 1.12-2.74 1.13 0.65-1.98 2.46 1.06-5.72
HA interfered with education 1.60 0.92-2.82 1.60 0.91-2.82 1.5 0.76-2.97
Less successful in career due do HA 2.19 1.43-3.37 2.19 1.23-3.89 1.77 0.90-3.51
Reduced earning due to HA 3.16 1.78-5.59 3.28 1.47-7.29 2.16 0.93-5.10
HA not understood by colleagues/employer 3.23- 1.85-5.64 3.40 1.65-6.99 2.59 1.04-6.48
HA not understood by family 3.54 1.68-7.48 4.50 1.54-13.12 2.19 0.76-6.33
Avoid telling people about HA 2.43 1.58-3.73 2.26 1.27-4.02 2.15 1.08-4.26
Feeling of being in control of the headaches 0.73 0.48-1.11 0.88 0.50-1.56 0.68 0.34-1.34
OR odds ratio, CI 95 % confidence interval, na not applicable
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having a major depression in patients with migraine was
as high as the risk for getting migraine in patients with
major depression, and the risk for major depression was
higher in persons with migraine compared to persons
without migraine [33]. A recent study found an in-
creased migraine frequency in patients with anxiety or
depression [14]. Our study was a cross-sectional study,
therefore odds ratios have to be interpreted cautiously.
Our data showed that the impact of depression and
anxiety on daily activities is high in patients with CH.
Over 80 % of the patients with CH and depression and/
or anxiety lost more than ten days of productivity, fam-
ily, social and leisure activities during the previous three
months. This may increase their risk of losing the job,
thus contributing to the lower socioeconomic status of
patients with chronic pain [5]. In contrast, the numbers
of lost days were comparable in the other study groups,
i.e. EH without and with depression and/or anxiety and
CH without depression and/or anxiety. Markedly more
patients in our study reported that their headaches inter-
fered with education, careers and earnings than in the
study of Steiner et al. [10], and these reports were even
higher in patients with depression and/or anxiety, al-
though not statistically significant. There is a substantial
impact on education, career and earnings in the patients’
perception. Lower education levels and lower socioeco-
nomic status were associated with an increased risk of
getting migraine [34], and patients with chronic mi-
graine were less likely to be working for pay than pa-
tients with episodic migraine [35]. So far, the impact of
Table 4 Summarized data for five classes of standard prophylactic medications (betablocker, flunarizine, valproate, topiramate,
amitriptyline) in patients with EH and CH with and without depression and/or anxiety, differentiating “none” or “one and more
prophylactics”. HADS scores ≥8 indicate presence of depression and/or anxiety, HADS scores <8 indicate absence of depression
and/or anxiety
EH (n = 232) CH (n = 160)
Anxiety and/or depression Statistics Anxiety and/or depression Statistics
Absent Present Absent Present
Patients Patients Chi2 p Patients Patients Chi2 p
n % n % n % n %
Ever-before use
Missing data: 27
None 59 45.7 40 44.9 27 50 39 41.9
One ore more prophylactics 70 54.3 49 55.1 27 50 54 58.1
Contraindications
Missing data: 43 4.4 0.037 ns
None 96 76.8 54 63.5 41 77.4 68 79.1
One or more 29 23.2 31 36.5 12 22.6 18 20.9
Adverse effects
Missing data: 25 ns ns
None 43 68.3 30 69.8 21 87.5 34 66.7
Caused by one or more prophylactics 20 31.7 13 30.2 3 12.5 17 33.3
Use for≥ 3 months
Missing data: 19 ns ns
None 17 26.6 7 14.9 5 19.2 9 18
One or more prophylactics 47 73.4 40 85.1 21 80.8 41 82
Intake of an adequate dose
Missing data: 23 ns ns
None 5 7.9 6 13.6 4 15.4 9 18
One or more prophylactics 58 92.1 38 86.4 22 84.6 41 82
Decrease in HA frequency by ≥ 50 %
Missing data: 33 ns ns
None 28 50.9 25 58.1 13 52 35 70
Caused by one or more prophylactics 27 49.1 18 41.9 12 48 15 30
ns not significant
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EH, CH and depression and/or anxiety on the employ-
ment status has not been studied.
Furthermore, social support was affected by the pres-
ence of anxiety and/or depression resulting in increased
risks of feeling less understood by the family, employer
and colleagues as well as an increased risk of avoiding to
tell other people about the headache. This was true for
the entire group of patients as well as for those with EH
and CH, with one exception. The difference for the
family’s understanding on ones headaches did not reach
the level of statistical significance in CH. In contrast,
D’Amico et al. [36] found only little evidence for the im-
pact of perceived social support on chronic migraine.
In accordance with other studies [25, 37] patients with
CH consulted general practitioners more often. In the
present subgroup analysis we did not find differences in
health care use and technical examinations between pa-
tients with and without depression and/or anxiety. But
the numbers of patients in each group were relatively
small, so we cannot draw a definite conclusion with
regards to the influence of depression and anxiety. A re-
cent study [38] found in-hospital stays six times, out-
patient visits four times and emergency department
visits three times as much in migraine patients with
compared to those without psychiatric comorbidities. In
addition the patients with psychiatric comorbidities
underwent computer tomography and magnetic reson-
ance imaging of the brain more often.
As in the main study the ever-before use of prophylac-
tic medication was low, but in contrast to the main
study the ever-before use did not differ between patients
with EH and CH [11]. This may be attributed to the
smaller patient number in the present analysis. More-
over the overall low use of prophylactic drugs may be
caused by patient or physician related factors: patients
may deny taking prophylactic drugs, neurologists may
try non-drug prophylaxis first, or especially physicians
who are not specialized in headache treatment may not
think of prophylactic drugs. We did not ask the treating
neurologists and patients for the reasons of not prescrib-
ing or taking prophylactics, and we are not aware of
other studies dealing with this issue. Interestingly, beta-
blocker and flunarizine, although having the potential of
triggering or worsening depression, had ever been used
by a substantial number of patients with depression and/
or anxiety. The neurologists assessed possible contrain-
dications based on the patient’s history and on their own
discretion. For clarity and comparability for each drug
the main contraindications according to the prescribing
information were listed in the questionnaire. The pre-
scription pattern in this study also reflects the treatment
of headache patients in neurological offices, as we in-
cluded patients who came for a first-time visit to one of
the headache centres as well as patients who came for a
control visit. Our findings emphasize that the choice of
prophylactic drugs needs to be improved, especially with
regards to depression and anxiety. Adverse effects, dur-
ation of prophylactic treatment, intake of an adequate
dose and decrease in headache frequency by ≥ 50 % did
not differ between patients with and without anxiety
and/or depression, but patient numbers in the groups
were too small do draw definite conclusions. Given the
impact of depression and anxiety on recurrent and
chronic headache further studies on therapeutic impact
are urgently needed. To the best of our knowledge no
previous study addressed this topic up till now.
Limitations of this study are the post-hoc analysis and
relatively small patient numbers in the subgroups of some
items. As this was an exploratory analysis, we did not cor-
rect for multiple testing. We did not analyse the dataset dif-
ferentiated by migraine, tension-type headache, pMOH and
other headaches or differentiated by anxiety alone, depres-
sion alone or anxiety and depression, because the sub-
groups would have been too small. The HADS is a
validated and widely used questionnaire for screening for
depression and anxiety, but it does not allow a clinical diag-
nosis of depression or anxiety, and patients in this study
did not undergo a psychiatric interview. Finally, we must
bear in mind that comorbidity rates in clinic-based studies
may be higher than in population-based studies because of
an increased vigilance or selection bias.
Strengths of the study are the large clinic-based sam-
ple from eight headache centres with high participation
rates, and the use of validated questionnaires for estab-
lishing headache diagnoses and for assessing depression
and anxiety.
Conclusion
This is one of the first studies looking at the impact of de-
pression and anxiety on EH and CH in a clinic-based pa-
tient sample. Patients with CH suffer from depression and/
or anxiety significantly more often than patients with EH.
More importantly, the quality of life is deceased and the
burden is further increased by depression and/or anxiety in
patients with EH and CH. In addition, treatment with
prophylactic medications is sub-optimal in patients with
depression and/or anxiety. In particular for these patients a
comprehensive treatment approach including pharmaco-
logical and non-pharmacological treatments (such as be-
havioural therapy, relaxation training, coping strategies) is
necessary in order to decrease disability on the personal, so-
cial and occupational level.
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